NCT06830720: A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Sponsor: Novartis Pharmaceuticals. Phase: . Conditions: Breast Neoplasms